{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:31:04Z","timestamp":1793647864821,"version":"4.5.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    We performed a Bayesian network meta-analysis to indirectly compare the relative efficacy and safety of the latest JAK inhibitors for moderate-to-severe alopecia areata (AA). 13 trials totaling 3,613 patients were included. Two low-dose groups of oral formulations (ritlecitinib 10mg and ivarmacitinib 2mg) and two topical formulations (delgocitinib ointment and ruxolitinib cream) appeared to be relatively ineffective against moderate-to-severe AA. Ranking analysis suggested that brepocitinib 30mg has the best relative effect in reducing the SALT score (sucra = 0.9831), and demonstrated comparable efficacy to deuruxolitinib 12mg (sucra = 0.9245), followed by deuruxolitinib 8mg (sucra = 0.7736). Regarding the SALT\n                    <jats:sub>50<\/jats:sub>\n                    response, brepocitinib 30mg ranked highest (sucra = 0.9567), followed by ritlecitinib 50mg (sucra = 0.8689) and deuruxolitinib 12mg (sucra = 0.7690). For achieving the SALT\n                    <jats:sub>75<\/jats:sub>\n                    response, deuruxolitinib 12mg had the highest probability (sucra = 0.9761), followed by deuruxolitinib 8mg (sucra = 0.8678) and brepocitinib 30mg (sucra = 0.8448). Deuruxolitinib 12mg might be the most effective therapy for patients with severe AA (sucra = 0.9395), followed by ritlecitinib 50mg (sucra = 0.8753) and deuruxolitinib 8mg (sucra = 0.8070). Deuruxolitinib 12mg\/8mg demonstrated notable efficacy for moderate-to-severe AA, and is expected to be a new treatment option for AA. It was worth noting that deuruxolitinib exhibit a greater likelihood of causing adverse events in comparison to other JAK inhibitors. Ritlecitinib 50mg seemed to exhibit fewer adverse effects in the high-dose groups of oral JAK inhibitors and might be an optimal choice to balance safety and efficacy. The majority of JAK inhibitors exhibited acceptable short-term safety profiles. To enhance the applicability and accuracy of our research, further head-to-head trials with longer follow-up periods are needed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Systematic Review Registration:<\/jats:bold>\n                    identifier [CRD42022368012].\n                  <\/jats:p>","DOI":"10.3389\/fphar.2024.1372810","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:48:35Z","timestamp":1712710115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Ting","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"adv00855","DOI":"10.2340\/actadv.v103.4536","article-title":"Comparative efficacy and safety of Janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis","volume":"103","author":"Barati Sedeh","year":"2023","journal-title":"Acta Derm. Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J. Am. Acad. Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"106490","DOI":"10.1016\/j.bioorg.2023.106490","article-title":"Deuterated driven new chemical entities: an optimistic way to improve therapeutic efficacy","volume":"135","author":"Chandra Mouli","year":"2023","journal-title":"Bioorg Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/pharmaceutics12121131","article-title":"Tofacitinib loaded squalenyl nanoparticles for targeted follicular delivery in inflammatory skin diseases","volume":"12","author":"Christmann","year":"2020","journal-title":"Pharmaceutics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e142205","DOI":"10.1172\/jci.insight.142205","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"key":"B6","doi-asserted-by":"publisher","first-page":"955038","DOI":"10.3389\/fimmu.2022.955038","article-title":"Induction of T cell exhaustion by JAK1\/3 inhibition in the treatment of alopecia areata","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J. Am. Acad. Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B9","unstructured":"Novel drug approvals for 20232023"},{"key":"B10","unstructured":"Approves first systemic treatment for alopecia areata2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19797","article-title":"Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: a systematic review and Bayesian network meta-analysis","author":"Husein-ElAhmed","year":"2024","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/s0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamadermatol.2023.2581","article-title":"Clinical outcomes for uptitration of baricitinib therapy in patients with severe alopecia areata: a pooled analysis of the BRAVE-AA1 and BRAVE-AA2 trials","volume":"159","author":"Ko","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1096\/fasebj.10.5.8621063","article-title":"Tec protein-tyrosine kinase is an effector molecule of Lyn protein-tyrosine kinase","volume":"10","author":"Mano","year":"1996","journal-title":"Faseb J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1002\/ski2.209","article-title":"Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata","volume":"3","author":"Mattsson","year":"2023","journal-title":"Skin. Health Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00403-022-02336-0","article-title":"A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata","volume":"315","author":"Mikhaylov","year":"2023","journal-title":"Arch. Dermatol Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.clindermatol.2018.08.011","article-title":"Psychosomatic aspects of alopecia areata","volume":"36","author":"Mulinari-Brenner","year":"2018","journal-title":"Clin. Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B29","volume-title":"ATI-501 oral suspension compared to placebo in subjects with alopecia areata","year":"2020"},{"key":"B30","unstructured":"Placebo-controlled safety study of ritlecitinib (pf-06651600) in adults with alopecia areata (allegro2a)2023"},{"key":"B31","unstructured":"Study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata (THRIVE-AA1)"},{"key":"B32","unstructured":"Study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata (THRIVE-AA2)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/13543784.2019.1568989","article-title":"New drugs under investigation for the treatment of alopecias","volume":"28","author":"Ocampo-Garza","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/s0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"114551","DOI":"10.1016\/j.ejmech.2022.114551","article-title":"Dual-target Janus kinase (JAK) inhibitors: comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases","volume":"239","author":"Shen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: a multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J. Autoimmun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J. Am. Acad. Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J. Am. Acad. Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1152513","DOI":"10.3389\/fimmu.2023.1152513","article-title":"Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ajd.13572","article-title":"Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib","volume":"62","author":"Yagi","year":"2021","journal-title":"Australas. J. Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"950450","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Zhou","year":"2023","journal-title":"J. Am. Acad. Dermatol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:48:40Z","timestamp":1712710120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":50,"alternative-id":["10.3389\/fphar.2024.1372810"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1372810","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"article-number":"1372810"}}